Lilly's obesity pill hits nearly 4000 prescriptions in second week after launch

Eli Lilly's newly launched oral weight loss drug Foundayo was prescribed 3,707 times in its second week, up from 1,390 in week one, but still well below Novo Nordisk's oral Wegovy, which logged 18,410 prescriptions in its second week. Analysts said the early uptake may be viewed negatively, though Lilly cautioned the figures are incomplete and too early to judge. Lilly shares were down 1.5% premarket while Novo's U.S.-listed shares rose 2%.

Analysis

The immediate read-through is not that Lilly has a weak product, but that Novo has a larger first-mover advantage than the market was assuming. In obesity pharmacotherapy, early prescription momentum can matter because physician habit formation, payer workflow, and patient persistence create a compounding effect; if a brand misses the initial “default choice” window, it often takes months, not weeks, to claw back share. That makes the next 4-8 weeks more important than the first two, because broad retail/telehealth normalization will tell us whether this is a distribution artifact or a real preference gap.

For NVO, the risk is less about incremental pill prescriptions in isolation and more about defending the category narrative while the market waits for a cleaner launch curve. A sustained lead in oral obesity could reinforce Novo’s reputation as the category setter, improving negotiation leverage with payers and providers across the broader incretin franchise. For Lilly, a slow start is most dangerous if it feeds a perception that its obesity pipeline is strong in injectables but less differentiated in convenience products, which could compress expectations for follow-on launches.

The most interesting second-order effect is on positioning rather than fundamentals. If investors extrapolate this early gap too aggressively, NVO can trade on sentiment multiple expansion while Lilly faces multiple compression despite both still having large addressable markets; that creates a tactical relative-value opportunity. The contrarian angle is that early weekly script data may undercount channel breadth and overstate brand preference, so any selloff in Lilly tied to one or two prints could reverse quickly once pharmacy access and prescriber learning normalize.

Key Decisions for Investors

• Short-term pair trade: long NVO / short LLY for 2-6 weeks, targeting continued sentiment divergence if weekly oral script momentum remains asymmetric; use a tight stop if Lilly's next print shows acceleration above Novo's week-over-week growth rate.
• For event-driven accounts, buy NVO call spreads 1-3 months out to express a modest continuation view on category leadership without paying full upside premium; best if implied volatility is still lagging headline momentum.
• Use any further 3-5% post-launch weakness in LLY to build a tactical long only if channel data improves, because the current setup looks more like a timing issue than a thesis break; risk/reward improves once distribution is fully online.
• Avoid chasing IQV on this headline alone; the data provider is not the economic winner, and this is more a sentiment event for pharma than a business-model inflection for IQV.
• Set a watchpoint on the next 2 weekly prescription prints: if Lilly closes 50%+ of the gap versus Novo, cover NVO relative longs quickly, since first-mover advantages in obesity can fade once payer and physician access standardizes.